These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 26902323)

  • 21. Screening for prostate cancer remains controversial.
    Stark JR; Mucci L; Rothman KJ; Adami HO
    BMJ; 2009 Sep; 339():b3601. PubMed ID: 19778971
    [No Abstract]   [Full Text] [Related]  

  • 22. Discuss prostate cancer screening with your doctor.
    The Lancet
    Lancet; 2017 Apr; 389(10079):1582. PubMed ID: 28443541
    [No Abstract]   [Full Text] [Related]  

  • 23. Group now advises against routine PSA screening.
    Mitka M
    JAMA; 2013 Jun; 309(22):2316. PubMed ID: 23757064
    [No Abstract]   [Full Text] [Related]  

  • 24. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
    Barry MJ; Mulley AJ
    J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
    [No Abstract]   [Full Text] [Related]  

  • 25. New US Preventive Service Task Force recommendations for prostate cancer screening: a needed update, but not enough.
    Wroclawski ML
    Einstein (Sao Paulo); 2017; 15(3):7-10. PubMed ID: 29091165
    [No Abstract]   [Full Text] [Related]  

  • 26. 2008 US Preventive Services Task Force recommendations and prostate cancer screening rates.
    Prasad SM; Drazer MW; Huo D; Hu JC; Eggener SE
    JAMA; 2012 Apr; 307(16):1692-4. PubMed ID: 22535850
    [No Abstract]   [Full Text] [Related]  

  • 27. Evaluation and Active Treatment versus Active Surveillance of Localized Prostate Cancer in Renal Transplant Patients in the Era of Low and Very Low Risk Prostate Cancer.
    Aminsharifi A; Simon R; Polascik TJ; Robertson CN; Sudan DL; Collins BH; Moul JW
    J Urol; 2019 Sep; 202(3):469-474. PubMed ID: 30835631
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stratifying risk--the U.S. Preventive Services Task Force and prostate-cancer screening.
    Schröder FH
    N Engl J Med; 2011 Nov; 365(21):1953-5. PubMed ID: 22029756
    [No Abstract]   [Full Text] [Related]  

  • 29. Prostate-specific antigen-based screening for prostate cancer in the third millennium: useful or hype?
    Lippi G; Montagnana M; Guidi GC; Plebani M
    Ann Med; 2009; 41(7):480-9. PubMed ID: 19657768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Counseling Patients About Prostate Cancer Screening.
    Stevermer JJ; Fink KS
    Am Fam Physician; 2018 Oct; 98(8):478-483. PubMed ID: 30277734
    [No Abstract]   [Full Text] [Related]  

  • 31. Screening for prostate cancer: time to put all the data on the table.
    Haines IE; Ablin RJ; Miklos GL
    BMJ; 2016 May; 353():i2574. PubMed ID: 27226459
    [No Abstract]   [Full Text] [Related]  

  • 32. One man at a time--resolving the PSA controversy.
    McNaughton-Collins MF; Barry MJ
    N Engl J Med; 2011 Nov; 365(21):1951-3. PubMed ID: 22029758
    [No Abstract]   [Full Text] [Related]  

  • 33. NCCN Guidelines Updates: Prostate Cancer and Prostate Cancer Early Detection.
    Carroll PH; Mohler JL
    J Natl Compr Canc Netw; 2018 May; 16(5S):620-623. PubMed ID: 29784740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Systematic PSA screening has been tried in Region Skåne. Balanced information gives chance for equal treatment according to a pilot project].
    Bratt O; Lundgren R; Ahlgren G
    Lakartidningen; 2012 Sep 12-18; 109(37):1610-2. PubMed ID: 23077769
    [No Abstract]   [Full Text] [Related]  

  • 35. Are age-based criteria the best way to determine eligibility for prostate cancer screening?
    Gogol M
    Ann Intern Med; 2009 Feb; 150(3):221; author reply 221-2. PubMed ID: 19189918
    [No Abstract]   [Full Text] [Related]  

  • 36. Are age-based criteria the best way to determine eligibility for prostate cancer screening?
    Konety BR; Cooperberg MR; Carroll PR
    Ann Intern Med; 2009 Feb; 150(3):220-1; author reply 221-2. PubMed ID: 19189916
    [No Abstract]   [Full Text] [Related]  

  • 37. [Prostate cancer screening: no proof of the benefit].
    Laplanche A; Hill C
    Presse Med; 2009 Oct; 38(10):1393-5. PubMed ID: 19647979
    [No Abstract]   [Full Text] [Related]  

  • 38. Screening for prostate cancer.
    Croswell J; Shin YR
    Am Fam Physician; 2013 Feb; 87(4):283-4. PubMed ID: 23418805
    [No Abstract]   [Full Text] [Related]  

  • 39. Introducing the 2010 American Cancer Society prostate cancer screening guideline.
    Brawley OW; Gansler T
    CA Cancer J Clin; 2010; 60(2):68-9. PubMed ID: 20200111
    [No Abstract]   [Full Text] [Related]  

  • 40. Correlation between stage shift and differences in mortality in the European Randomised study of Screening for Prostate Cancer (ERSPC).
    Bokhorst LP; Zappa M; Carlsson SV; Kwiatkowski M; Denis L; Paez A; Hugosson J; Moss S; Auvinen A; Roobol MJ
    BJU Int; 2016 Nov; 118(5):677-680. PubMed ID: 27104278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.